In a deal potentially worth up to $420mm Aerpio Pharmaceuticals Inc. licensed Gossamer Bio Inc. exclusive global rights to develop and commercialize AKB4924 and related compounds for inflammatory bowel diseases including ulcerative colitis and Crohns disea...
↧